In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473).
We enrolled patients with metastatic RCC with no prior checkpoint inhibitor exposure.